| Literature DB >> 23217418 |
Chris Mason1, Mark J McCall, Emily J Culme-Seymour, Shalini Suthasan, Simon Edwards-Parton, Gregory A Bonfiglio, Brock C Reeve.
Abstract
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.Mesh：
Year: 2012 PMID： 23217418 DOI： 10.1016/j.stem.2012.11.013
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633